Latent autoimmune diabetes in adults (LADA): Usefulness of anti-GAD antibody titers and benefit of early insulinization

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 51, Issue 1, 2007, Pages 52-58

  Rosário, Pedro Weslley Souza ^a,b   Reis, Janice Sepulveda ^a   Fagundes, Tiago Alvarenga ^a   Calsolari, Maria Regina ^a   Amim, Ricardo ^a   Silva, Saulo Cavalcanti ^a   Purisch, Saulo ^a  

^a Endocrinology Service   (Brazil)

^b Centro de Estudos e Pesquisa da Clinica de Endocrinologia e Metabologia CEPCEM   (Brazil)

Author keywords

GADA titers; Insulinization; LADA

Indexed keywords

ANTIDIABETIC AGENT; AUTOANTIBODY; BIOLOGICAL MARKER; C PEPTIDE; GLUTAMATE DECARBOXYLASE; INSULIN;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; AUTOIMMUNE DISEASE; BODY MASS; DIABETES MELLITUS; DIFFERENTIAL DIAGNOSIS; FEMALE; FOLLOW UP; HUMAN; IMMUNOLOGY; INSULIN RESISTANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONPARAMETRIC TEST; PHYSIOLOGY;

ADULT; ANALYSIS OF VARIANCE; AUTOANTIBODIES; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; BODY MASS INDEX; C-PEPTIDE; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; DIAGNOSIS, DIFFERENTIAL; FEMALE; FOLLOW-UP STUDIES; GLUTAMATE DECARBOXYLASE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; MALE; STATISTICS, NONPARAMETRIC;

EID: 34247146490     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302007000100009     Document Type: Article

References (42)

1. Pozzilli P, Di Mario U. Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention. Diabetes Care 2001;24:1460-7.
2. Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR, et al. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 1997;350:1288-93.
3. Hosszufalusi N, Vatay A, Rajczy K, Prohaszka Z, Pozsonyi E, Horvath L, et al. Similar genetic features and different islet cell autoantibody pattern of latent autoimmune diabetes in adults (LADA) compared with adult-onset type 1 diabetes with rapid progression. Diabetes Care 2003;26:452-7.
4. Tuomi T, Carlsson A, Li H, Isomaa B, Miettinen A, Nilsson A, et al. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 1999;48:150-7.
5. Isomaa B, Almgren P, Henricsson M, Taskinen MR, Tuomi T, Groop L, et al. Chronic complications in patients with slowly progressing autoimmune type 1 diabetes (LADA). Diabetes Care 1999;22:1347-53.
6. Zinman B, Kahn SE, Haffner SM, O'Neill MC, Heise MA, Freed MI (ADOPT Study Group). Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe. Diabetes 2004;53:3193-200.
7. Lohmann T, Kellner K, Verlohren HJ, Krug J, Steindorf J, Scherbaum WA, et al. Titre and combination of ICA and autoantibodies to glutamic acid decarboxylase discriminate two clinically distinct types of latent autoimmune diabetes in adults (LADA). Diabetologia 2001;44:1005-10.
8. Palmer JP, Hirsch IB. What's in a name: Latent autoimmune diabetes of adults, type 1.5, adult-onset, and type 1 diabetes. Diabetes Care 2003;26:536-8.
9. Takino H, Yamasaki H, Abiru N, Sera Y, Abe T, Kawasaki E, et al. Antibodies to GAD in Japanese patients classified as type 2 diabetes at diagnosis. High titre of GADAb is a predictive marker for early insulin treatment - report of west Japan (Kyushu, Yamaguchi, Osaka) study for GADAb(+) diabetes. Diabet Med 2002;19:730-4.
10. Maruyama T, Shimada A, Kanatsuka A, Kasuga A, Takei I, Yokoyama J, et al. Multicenter prevention trial of slowly progressive type 1 diabetes with small dose of insulin (the Tokyo study): preliminary report. Ann N Y Acad Sci 2003;1005:362-9.
11. Kobayashi T, Maruyama T, Shimada A, Kasuga A, Kanatsuka A, Takei I, et al. Insulin intervention to preserve beta cells in slowly progressive insulin-dependent (type 1) diabetes mellitus. Ann N Y Acad Sci 2002;958:117-30.
12. Rosário PW, Reis JS, Amim R, Fagundes TA, Calsolari MR, Silva SC, et al. Comparison of clinical and laboratory characteristics between adult-onset type 1 diabetes and latent autoimmune diabetes in adults. Diabetes Care 2005;28:1803-4.
13. Prando R, Cheli V, Melga P, Giusti R, Ciuchi E, Odetti P. Is type 2 diabetes a different disease in obese and nonobese patients? Diabetes Care 1998;21:1680-5.
14. 125I-labelled recombinant GAD65 produced in yeast. Clin Chim Acta 1996;256:175-88.
15. Pardini VC, Mourão DM, Nascimento PD, Vivolo MA, Ferreira SR, Pardini H. Frequency of islet cell autoantibodies (IA-2 and GAD) in young Brazilian type 1 diabetes patients. Braz J Med Biol Res 1999;32:1195-8.
16. Bingley PJ, Bonifacio E, Mueller PW. Diabetes antibody standardization program: First assay proficiency evaluation. Diabetes 2003;52:1128-36.
17. Emoto M, Nishizawa Y, Maekawa K, Hiura Y, Kanda H, Kawagishi T, et al. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care 1999;22:818-22.
18. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000;23:57-63.
19. Hother-Nielsen O, Faber O, Sorensen NS, Beck-Nielsen H. Classification of newly diagnosed diabetic patients as insulin-requiring or non-insulin-requiring based on clinical and biochemical variables. Diabetes Care 1988;11:531-7.
20. Carlsson A, Sundkvist G, Groop L, Tuomi T. Insulin and glucagon secretion in patients with slowly progressing autoimmune diabetes (LADA). J Clin Endocrinol Metab 2000;85:76-80.
21. Borg H, Gottsater A, Landin-Olsson M, Fernlund P, Sundkvist G. High levels of antigen-specific islet antibodies predict future beta-cell failure in patients with onset of diabetes in adult age. J Clin Endocrinol Metab 2001;86:3032-8.
22. Li X, Yang L, Zhou Z, Huang G, Yan X. Glutamic acid decarboxylase 65 autoantibody levels discriminate two subtypes of latent autoimmune diabetes in adults. Chin Med J (Engl) 2003;116:1728-32.
23. Hamaguchi K, Kimura A, Kusuda Y, Yamashita T, Yasunami M, Takahasi M, et al. Clinical and genetic characteristics of GAD-antibody positive patients initially diagnosed as having type 2 diabetes. Diabetes Res Clin Pract 2004;66:163-71.
24. Gottsater A, Landin-Olsson M, Lernmark A, Fernlund P, Sundkvist G, Hagopian WA. Glutamate decarboxylase antibody levels predict rate of beta-cell decline in adult-onset diabetes. Diabetes Res Clin Pract 1995;27:133-40.
25. Kasuga A, Maruyama T, Ozawa Y, Takei I, Falorni A, Lernmark A, et al. Antibody to the M(r) 65,000 isoform of glutamic acid decarboxylase are detected in non-insulin-dependent diabetes in Japanese. J Autoimmun 1996;9:105-11.
26. Kasuga A, Maruyama T, Nakamoto S, Ozawa Y, Suzuki Y, Saruta T. High-titer autoantibodies against glutamic acid decarboxylase plus autoantibodies against insulin and IA-2 predicts insulin requirement in adult diabetic patients. J Autoimmun 1999;12:131-5.
27. Takeda H, Kawasaki E, Shimizu I, Konoue E, Fujiyama M, Murao S, et al;Ehime Study. Clinical, autoimmune, and genetic characteristics of adult-onset diabetic patients with GAD autoantibodies in Japan (Ehime Study). Diabetes Care 2002;25:995-1001.
28. Borg H, Gottsater A, Fernlund P, Sundkvist G. A 12-year prospective study of the relationship between islet antibodies and beta-cell function at and after the diagnosis in patients with adult-onset diabetes. Diabetes 2002;51:1754-62.
29. Falorni A, Calcinaro F. Autoantibody profile and epitope mapping in latent autoimmune diabetes in adults. Ann N Y Acad Sci 2002;958:99-106.
30. Falorni A, Gambelunghe G, Forini F, Kassi G, Cosentino A, Candeloro P, et al. Autoantibody recognition of COOH-terminal epitopes of GAD65 marks the risk for insulin requirement in adult-onset diabetes mellitus. J Clin Endocrinol Metab 2000;85:309-16.
31. Ziegler B, Strebelow M, Rjasanowski I, Schlosser M, Ziegler M. A monoclonal antibody-based characterization of autoantibodies against glutamic acid decarboxylase in adults with latent autoimmune diabetes. Autoimmunity 1998;28:61-8.
32. Tsuruoka A, Matsuba I, Toyota T, Isshiki G, Nagataki S, Ikeda Y. Antibodies to GAD in Japanese diabetic patients: a multicenter study. Diabetes Res Clin Pract 1995;28:191-9.
33. Fukui M, Nakamura N, Nakano K, Kajiyama S, Matsuo S, Obayashi H, et al. HLA-associated cellular response to GAD in type 2 diabetes with antibodies to GAD. Endocrine J 2000;47:753-61.
34. Kobayashi T, Nakanishi K, Okubo M, Murase T, Kosaka K. GAD antibodies seldom disappear in slowly progressive IDDM (Letter). Diabetes Care 1996;19:1031.
35. Decochez K, Tits J, Coolens JL, Van Gaal L, Krzentowski G, Winnock F, et al. High frequency of persisting or increasing islet-specific autoantibody levels after diagnosis of type 1 diabetes presenting before 40 years of age. The Belgian Diabetes Registry. Diabetes Care 2000;23:838-44.
36. Niskanen LK, Tuomi T, Karjalainen J, Groop LC, Uusitupa MI. GAD antibodies in NIDDM. Ten-year follow-up from the diagnosis. Diabetes Care 1995;18:1557-65.
37. Gambelunghe G, Forini F, Laureti S, Murdolo G, Toraldo G, Santeusanio F, et al. Increased risk for endocrine autoimmunity in Italian type 2 diabetic patients with GAD65 autoantibodies. Clin Endocrinol (Oxf) 2000;52:565-73.
38. Kobayashi T, Nakanishi K, Murase T, Kosaka K. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes 1996;45:622-6.
39. Cabrera-Rode E, Perich P, Diaz-Horta O, Tiberti C, Molina G, Arranz C, et al. Slowly progressing type 1 diabetes: persistence of islet cell autoantibodies is related to glibenclamide treatment. Autoimmunity 2002;35:469-74.
40. Beales PE, Pozzilli P. Thiazolidinediones for the prevention of diabetes in the non-obese diabetic (NOD) mouse: implications for human type 1 diabetes. Diab Metab Res Rev 2002;18:114-7.
41. Zhou Z, Li X, Huang G, Peng J, Yang L, Yan X, et al. Rosiglitazone combined with insulin preserves islet beta cell function in adult-onset latent autoimmune diabetes (LADA). Diab Metab Res Rev 2005;21:203-8.
42. Gottsater A, Landin-Olsson M, Lernmark A, Fernlund P, Sundkvist G. Islet cell antibodies are associated with β-cell failure also in obese adult onset diabetic patients. Acta Diabetol 1994;31:226-31.